New combo before surgery shows promise against advanced rectal cancer
NCT ID NCT06647680
First seen Mar 17, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study tests whether giving chemotherapy plus the immunotherapy drug Tislelizumab before surgery can shrink advanced rectal cancer and improve outcomes. About 35 adults with stage T3 or T4 rectal cancer will receive the combination for three cycles, then have surgery. Researchers will monitor how many patients have a complete response (no cancer detectable) and track safety and long-term results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER PATIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The affiliated hospital of Qingdao university
RECRUITINGQingdao, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.